Oral VK2735
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
Viking Therapeutics · Phase 3 · Not yet recruiting · Enrollment 560
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo Assignment | Obesity or overweight | n/r | n/r | n/r | n/r |
| Active Assignment (Dose 1) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Active Assignment (Dose 2) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Active Assignment (Dose 3) | Obesity or overweight | n/r | n/r | n/r | n/r |